<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03829033</url>
  </required_header>
  <id_info>
    <org_study_id>Version 2 2018-10-10</org_study_id>
    <nct_id>NCT03829033</nct_id>
  </id_info>
  <brief_title>Photon Therapy Versus Proton Therapy in Early Tonsil Cancer.</brief_title>
  <acronym>ARTSCAN V</acronym>
  <official_title>Photon Therapy Versus Proton Therapy in Early Tonsil Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lund University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this trial, patients with early squamous cell carcinoma of the tonsil with clinical stage
      T1-2 (p16-positive or p16-negative) N0-1 (p16-positive)/N0-N2b (p16-negative) according to
      American Joint Committee on Cancer (AJCC) 8th edition, aimed for unimodal and ipsilateral
      treatment with radiotherapy with curative intent will be included. The patients will be
      randomized to in a 1:1 ratio to receive radiotherapy with either photons (conventional
      radiotherapy) versus radiotherapy with protons.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2019</start_date>
  <completion_date type="Anticipated">January 2028</completion_date>
  <primary_completion_date type="Anticipated">January 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute side effects.</measure>
    <time_frame>From the third week of radiotherapy, and then weekly during radiotherapy, which ends after 7 weeks.</time_frame>
    <description>Locoregional side effects (mucositis, pain, dysphagia, skin reactions and other functional impairment) are monitored weekly according to a modified morbidity scoring scale based on Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer (RTOG/EORTC). Acute radiation morbidity scoring criteria and other side effects are graded according to (Common Toxicity Criteria for Adverse Events (CTCAE) v4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Late side effects.</measure>
    <time_frame>At 2-3 months after completed radiotherapy, then every 3 month for 2 years, and then every 6 month until 5 years.</time_frame>
    <description>Locoregional side effects (mucositis, pain, dysphagia, skin reactions and other functional impairment) are monitored according to a modified morbidity scoring scale based on Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer (RTOG/EORTC). Late radiation morbidity scoring criteria and other side effects are graded according to Common Toxicity Criteria for Adverse Events (CTCAE) v4.0.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Tonsil Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy delivered with photons</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy delivered with protons</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiotherapy with either photons or protons.</description>
    <arm_group_label>Radiotherapy delivered with photons</arm_group_label>
    <arm_group_label>Radiotherapy delivered with protons</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient must be at least 18 years old.

          2. Histologically or cytologically confirmed, previously untreated squamous cell
             carcinoma of the tonsil T1-2 (p16-positive or p16-negative) N0-1 M0
             (p16-positive)/N0-N2b M0 (p16-negative) according to AJCC 8th edition, aimed for
             unimodal and ipsilateral treatment with radiotherapy with curative intent. The
             treatment may be followed but not preceded by surgery, which would be as a salvage
             procedure and not part of the planned treatment. An excision of a lymph node, or a
             tonsillectomy for diagnostic purposes does not exclude the patient from participation.

          3. World Health Organisation/Eastern Cooperative Oncology Group (WHO/ECOG) performance
             status 0-1.

          4. The patient must be able to understand the information about the treatment and give a
             written informed consent.

        Exclusion Criteria:

          1. Patients judged to benefit from bilateral radiotherapy or concomitant chemotherapy

          2. Concomitant or previous malignancies. Exceptions are adequately treated basal cell
             carcinoma or squamous cell carcinoma of the skin, or in situ carcinoma of the cervix
             uteri with a follow-up time of at least 3 years, or other previous malignancy with a
             disease-free interval of at least 5 years.

          3. Two or more synchronous primary cancers in the head and neck region at time of
             diagnosis

          4. Previous surgery or radiotherapy in the head and neck region that may affect the study
             result, as judged by the investigator

          5. Co-existing disease prejudicing survival (expected survival should be &gt;2 years).

          6. Psychiatric or addictive disorders or other medical conditions which in the view of
             the investigator might impair patient compliance

          7. When dental fillings with amalgam or metal are present close to the tumour area it
             must be considered if this may affect radiotherapy before inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Gebre-Medhin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University Hospiyal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Gebre-Medhin, MD</last_name>
    <phone>+46 46 17 75 20</phone>
    <email>maria.gebre-medhin@skane.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Iréne Schönström, RN</last_name>
    <phone>+46 46 17 85 59</phone>
    <email>irene.schonstrom@skane.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gävle Hospital</name>
      <address>
        <city>Gävle</city>
        <zip>SE-803 24</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann-Sofie Fransson, MD</last_name>
      <phone>+46 26 15 40 00</phone>
      <email>ann-sofie.fransson@regiongavleborg.se</email>
    </contact>
    <investigator>
      <last_name>Ann-Sofie Fransson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-413 46</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hedda Haugen, MD</last_name>
      <phone>+46 31 343 60 42</phone>
      <email>hedda.haugen@oncology.gu.se</email>
    </contact>
    <investigator>
      <last_name>Hedda Haugen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jönköping Hospital</name>
      <address>
        <city>Jönköping</city>
        <zip>SE-553 05</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mattias Olin, MD</last_name>
      <phone>+46 10 24 25 942</phone>
      <email>mattias.olin@rjl.se</email>
    </contact>
    <investigator>
      <last_name>Mattias Olin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karlstad Hospital</name>
      <address>
        <city>Karlstad</city>
        <zip>SE-652 30</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Britta Lödén, MD</last_name>
      <phone>+46 54 61 50 00</phone>
      <email>britta.loden@regionvarmland.se</email>
    </contact>
    <investigator>
      <last_name>Britta Lödén, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <zip>SE-587 50</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Flejmer, MD</last_name>
      <phone>+46 10 103 00 00</phone>
      <email>anna.maria.flejmer@regionostergotland.se</email>
    </contact>
    <investigator>
      <last_name>Anna Flejmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Gebre-Medhin, MD</last_name>
      <phone>+46 46 17 75 20</phone>
      <email>maria.gebre-medhin@skane.se</email>
    </contact>
    <investigator>
      <last_name>Maria Gebre-Medhin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 64</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Gubanski, MD</last_name>
      <phone>+46 8 517 700 00</phone>
      <email>michael.gubanski@sll.se</email>
    </contact>
    <investigator>
      <last_name>Michael Gubanski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Umeå</city>
        <zip>SE-907 37</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Björn Zackrisson, MD</last_name>
      <phone>+46 90 785 00 00</phone>
      <email>bjorn.zackrisson@onkologi.umu.se</email>
    </contact>
    <investigator>
      <last_name>Björn Zackrisson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scandion clinic</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-752 37</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna Färlin, MD</last_name>
      <phone>+46 18 495 80 00</phone>
      <email>johanna.farlin@skandion.se</email>
    </contact>
    <investigator>
      <last_name>Johanna Färlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uppsala Accademical Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-753 09</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zahra Taheri Kadkhoda, MD</last_name>
      <phone>+46 18 611 00 00</phone>
      <email>zahra.taheri.kadkhoda@akademiska.se</email>
    </contact>
    <investigator>
      <last_name>Zahra Taheri Kadkhoda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Västmanlands Hospital</name>
      <address>
        <city>Västerås</city>
        <zip>SE-723 35</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zizana Lovasova, MD</last_name>
      <phone>+46 21 17 39 04</phone>
      <email>zuzana.lovasova@regionvastmanland.se</email>
    </contact>
    <investigator>
      <last_name>Zuzana Lovasova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <zip>SE-703 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Lundin, MD</last_name>
      <phone>+46 19 602 10 00</phone>
      <email>erik.lundin@regionorebrolan.se</email>
    </contact>
    <investigator>
      <last_name>Erik Lundin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 1, 2019</study_first_submitted>
  <study_first_submitted_qc>February 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2019</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tonsil Cancer</keyword>
  <keyword>Early Tonsil Cancer</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Photons</keyword>
  <keyword>Protons</keyword>
  <keyword>Acute Side Effects</keyword>
  <keyword>Late Side Effects</keyword>
  <keyword>Locoregional Control</keyword>
  <keyword>Disease Free Survival</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Health Economic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tonsillar Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

